keyword
MENU ▼
Read by QxMD icon Read
search

"Non-small cell lung cancer" AND gemcitabine

keyword
https://www.readbyqxmd.com/read/28927112/non-small-cell-lung-cancer-pc-9-cells-exhibit-increased-sensitivity-to-gemcitabine-and-vinorelbine-upon-acquiring-resistance-to-egfr-tyrosine-kinase-inhibitors
#1
Junko Hamamoto, Hiroyuki Yasuda, Kaito Aizawa, Makoto Nishino, Shigenari Nukaga, Toshiyuki Hirano, Ichiro Kawada, Katsuhiko Naoki, Tomoko Betsuyaku, Kenzo Soejima
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) are widely used for the treatment of non-small cell lung cancers (NSCLCs) harboring EGFR-activating mutations. However, lung cancer cells inevitably acquire resistance to these EGFR-TKIs. The majority of patients whose lung cancer acquires resistance to EGFR-TKIs are subjected to treatment using cytotoxic agents. The present study aimed to determine if lung cancer cells acquiring resistance to EGFR-TKIs also develop altered sensitivity to cytotoxic agents...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28919713/layer-by-layer-nanoparticles-co-loading-gemcitabine-and-platinum-iv-prodrugs-for-synergistic-combination-therapy-of-lung-cancer
#2
Rongrong Zhang, Yun Ru, Yiping Gao, Jinyin Li, Shilong Mao
PURPOSE: Cisplatin plus gemcitabine (GEM) is a standard regimen for the first-line treatment of advanced non-small cell lung cancer. The aim of this study was to prepare biocompatible and biodegradable polymeric prodrugs and construct nanoparticles (NPs) with layer-by-layer (LbL) technique. METHODS: Platinum (Pt) (IV) complex with a carboxyl group was conjugated to the amino group of chitosan (CH), resulting in a CH-Pt conjugation with positive charge. GEM with amino group was conjugated to the carboxyl group of hyaluronic acid (HA), resulting in a HA-GEM conjugation with negative charge...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28911085/a-randomized-open-label-multicenter-phase-3-study-to-compare-the-efficacy-and-safety-of-eribulin-to-treatment-of-physician-s-choice-in-patients-with-advanced-non-small-cell-lung-cancer
#3
N Katakami, E Felip, D R Spigel, J-H Kim, M Olivo, M Guo, H Nokihara, J C-H Yang, N Iannotti, M Satouchi, F Barlesi
Background: Eribulin is a microtubule dynamics inhibitor with a novel mechanism of action. This phase 3 study aimed to compare overall survival (OS) in patients with heavily pretreated non-small cell lung cancer (NSCLC) receiving eribulin to treatment of physician's choice (TPC). Patients and methods: Patients with advanced NSCLC who had received ≥2 prior therapies, including platinum-based doublet and epidermal growth factor receptor tyrosine kinase inhibitor, were randomly assigned to receive eribulin or TPC (gemcitabine, pemetrexed, vinorelbine, docetaxel)...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28860832/a-cost-effectiveness-analysis-of-first-line-induction-and-maintenance-treatment-sequences-in-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer-in-france
#4
Kaisa Taipale, Katherine B Winfree, Mark Boye, Mickael Basson, Ghassan Sleilaty, James Eaton, Rachel Evans, Christos Chouaid
BACKGROUND: Comparative effectiveness and cost-effectiveness data for induction-maintenance (I-M) sequences for the treatment of patients with nonsquamous non-small-cell lung cancer (nsqNSCLC) are limited because of a lack of direct evidence. This analysis aimed to compare the cost-effectiveness of I-M pemetrexed with those of other I-M regimens used for the treatment of patients with advanced nsqNSCLC in the French health-care setting. MATERIALS AND METHODS: A previously developed global partitioned survival model was adapted to the France-only setting by restricting treatment sequences to include 12 I-M regimens most relevant to France, and incorporating French costs and resource-use data...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28845737/biodistribution-study-of-99m-tc-gemcitabine-loaded-spherulites-in-sprague-dawley-rats-by-gamma-scintigraphy-to-investigate-its-lung-targeting-potential
#5
Rahul Dhande, Amit Tyagi, Rakesh Kumar Sharma, Hetal Thakkar
Gemcitabine Hydrochloride (GCH) is drug of choice for treatment of Non-Small Cell Lung Cancer. This project aims to formulate GCH loaded Spherulites for lung targeting using Soyabean Phosphatidylcholine, Cholesterol and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]. Vesicles were characterized for size, entrapment efficiency, drug release and in vitro cytotoxicity. Radiolabeling of GCH was done using reduced technetium-99m to study biodistribution in Sprague Dawley rats...
August 28, 2017: Journal of Microencapsulation
https://www.readbyqxmd.com/read/28839994/transcutaneous-electrical-acupoint-stimulation-teas-relieved-cancer-related-fatigue-in-non-small-cell-lung-cancer-nsclc-patients-after-chemotherapy
#6
Lili Hou, Caicun Zhou, Yifan Wu, Ying Yu, Yinqing Hu
BACKGROUND: To explore the effectiveness of transcutaneous electrical acupoint stimulation (TEAS) approach on cancer-related fatigue (CRF) in non-small cell lung cancer (NSCLC) chemotherapy patients. METHODS: A total of 162 participants who treated with gemcitabine combined with platinum-based drugs (GP chemotherapy) were randomly assigned to three groups: Control (Group A, n=56), Sham TEAS (Group B, n=49), and TEAS (Group C, n=57). The following acupoints were used in this study: Qihai (CV6), Keshu (UB17), and Zusanli (ST36)...
July 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28814805/intercalating-and-maintenance-gefitinib-plus-chemotherapy-versus-chemotherapy-alone-in-selected-advanced-non-small-cell-lung-cancer-with-unknown-egfr-status
#7
Hong Jian, Wei Li, Zhiyong Ma, Jianjin Huang, Jifeng Feng, Yong Song, Beili Gao, Huili Zhu, Min Tao, Chong Bai, Shenglin Ma, Hongming Pan, Shukui Qin, Dong Hua, Yongfeng Yu, Shun Lu
Epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) are standard treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. However, EGFR mutation testing is not attainable in approximately 20% of patients. The current study examined intercalating and maintaining gefitinib treatment in stage IIIB/IV non-squamous NSCLC, never or former light smoking patients with unknown EGFR mutation status. Briefly, 219 patients who achieved stable disease (SD) with gemcitabine (1250 mg/m(2)) plus carboplatin (5 AUC) were randomized at 1:1 ratio to continue chemotherapy (n = 110) or intercalating gefitinib (250 mg/day on days 15-25 of each cycle until disease progress (n = 109)...
August 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28806963/effectiveness-outcomes-and-health-related-quality-of-life-impact-of-disease-progression-in-patients-with-advanced-nonsquamous-nsclc-treated-in-real-world-community-oncology-settings-results-from-a-prospective-medical-record-registry-study
#8
Mark S Walker, William Wong, Arliene Ravelo, Paul J E Miller, Lee S Schwartzberg
BACKGROUND: Treatment options for advanced nonsquamous non-small cell lung cancer (NSCLC) in the first line include platinum-based doublet therapy with or without bevacizumab. This study examined efficacy outcomes and patient reported outcomes (PROs) in a community oncology patient sample. METHODS: Advanced nonsquamous NSCLC patients from 34 U.S. community oncology practices treated in first line with bevacizumab regimens (A platinum doublet; gemcitabine doublet; pemetrexed with platinum) or non-bevacizumab regimens (B platinum doublet; gemcitabine doublet; C pemetrexed with platinum) were recruited for this prospective study...
August 14, 2017: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/28780466/carboplatin-versus-two-doses-of-cisplatin-in-combination-with-gemcitabine-in-the-treatment-of-advanced-non-small-cell-lung-cancer-results-from-a-british-thoracic-oncology-group-randomised-phase-iii-trial
#9
RANDOMIZED CONTROLLED TRIAL
David Ferry, Lucinda Billingham, Hugh Jarrett, David Dunlop, Penella J Woll, Marianne Nicolson, Riyaz Shah, Joyce Thompson, James Spicer, D Muthukumar, Geraldine Skailes, Pauline Leonard, A D Chetiyawardana, Paula Wells, Conrad Lewanski, Barbara Crosse, Michelle Hill, Piers Gaunt, Kenneth O'Byrne
BACKGROUND: Platinum-based combination chemotherapy is standard treatment for the majority of patients with advanced non-small-cell lung cancer (NSCLC). The trial investigates the importance of the choice of platinum agent and dose of cisplatin in relation to patient outcomes. METHODS: The three-arm randomised phase III trial assigned patients with chemo-naïve stage IIIB/IV NSCLC in a 1:1:1 ratio to receive gemcitabine 1250 mg/m(2) on days 1 and 8 of a 3-week cycle with cisplatin 80 mg/m(2) (GC80) or cisplatin 50 mg/m(2) (GC50) or carboplatin AUC6 (GCb6) for a maximum of four cycles...
September 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28760000/cholesterol-derivative-based-liposomes-for-gemcitabine-delivery-preparation-in-vitro-and-in-vivo-characterization
#10
Tang Li, Li Chen, Yihui Deng, Xinrong Liu, Xiaoyun Zhao, Yiwen Cui, Jia Shi, Rui Feng, Yanzhi Song
As an anti-tumor drug, gemcitabine (Gem) is commonly used for the treatment of non-small cell lung cancer and pancreatic cancer. However, there are several clinical drawbacks to using Gem, including its extremely short plasma half-life and side effects. To prolong its half-life and reduce its side effects, we synthesized a derivative of Gem using cholesterol (Chol). This derivative, called gemcitabine-cholesterol (Gem-Chol) was entrapped into liposomes by a thin-film dispersion method. The particle size of the Gem-Chol liposomes was 112...
August 1, 2017: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/28745824/gemcitabine-combined-with-cisplatin-as-adjuvant-chemotherapy-for-non-small-cell-lung-cancer-a-retrospective-analysis
#11
Di Ma, Jing Wang, Xuezhi Hao, Yan Wang, Xingsheng Hu, Puyuan Xing, Junling Li
BACKGROUND: This study was conducted to evaluate the value of gemcitabine combined with cisplatin as adjuvant chemotherapy for radical resection of non-small cell lung cancer. METHODS: Data of 100 patients who had undergone radical resection of non-small cell lung cancer and were treated with cisplatin/gemcitabine as adjuvant chemotherapy between June 2007 and December 2010 at the Chinese Academy of Medical Sciences were reviewed. RESULTS: The median age was 59 years (range 36-73); 82% of the patients were male...
September 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28743280/exosomes-derived-from-gemcitabine-resistant-cells-transfer-malignant-phenotypic-traits-via-delivery-of-mirna-222-3p
#12
Feng Wei, Chengyuan Ma, Tong Zhou, Xuechao Dong, Qinghua Luo, Li Geng, Lijuan Ding, Yandong Zhang, Li Zhang, Nan Li, Yang Li, Yan Liu
BACKGROUND: Although gemcitabine-based chemotherapy has been established as a core multimodal therapy for non-small cell lung cancer (NSCLC) treatment, its clinical efficacy remains limited by the development of acquired resistance following tumor metastasis and relapse. In this study, we investigated how gemcitabine-resistant (GR) cells contribute to the development of NSCLC tumor malignancy via exosome-mediated transfer of microRNAs. METHODS: We first studied the mechanism of exosome internalization via PKH-67 staining and an immunofluorescence assay, then confirmed our finding by transmission electron microscopy and western blot analysis...
July 25, 2017: Molecular Cancer
https://www.readbyqxmd.com/read/28693283/prospective-exploratory-study-of-gemcitabine-and-s-1-against-elderly-patients-with-advanced-non-small-cell-lung-cancer
#13
Kyoichi Kaira, Noriko Yanagitani, Noriaki Sunaga, Hisao Imai, Akihiro Ono, Yasuhiko Koga, Takeshi Hisada, Tamotsu Ishizuka, Masanobu Yamada
A prospective study was conducted to investigate the efficacy of a combined regimen of gemcitabine and S-1 for the treatment of elderly patients (>70 years) with advanced non-small cell lung cancer (NSCLC) as a first-line setting based on the dosage recommended in a previous phase I study. Chemotherapy-naïve patients with advanced NSCLC received gemcitabine plus S-1. S-1 (40 mg/m(2)) was administered orally twice daily for 14 days while gemcitabine (1,000 mg/m(2)) was administered on days 1 and 15 of each cycle, and this regimen was repeated every 4 weeks...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28668866/histology-based-combination-induction-chemotherapy-for-elderly-patients-with-clinical-stage-iii-non-small-cell-lung-cancer
#14
Giuseppe L Banna, Hector Josè Soto Parra, Marine Castaing, Maria Vittoria Dieci, Giuseppe Anile, Maurizio Nicolosi, Salvatore Strano, Francesco Marletta, Valentina Guarneri, Pierfranco Conte, Rohit Lal
AIM: To explore the feasibility and activity of a histology-based induction combination chemotherapy for elderly patients with clinical stage III non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients aged ≥70 years with stage IIIA and IIIB lung squamous cell carcinoma (SCC) or adenocarcinoma were treated with three cycles of carboplatin and gemcitabine or pemetrexed, respectively, followed by definitive radiotherapy or surgery. The primary endpoint was the overall response rate (ORR) following induction...
July 2017: Anticancer Research
https://www.readbyqxmd.com/read/28577946/reduced-smad4-expression-and-dna-topoisomerase-inhibitor-chemosensitivity-in-non-small-cell-lung-cancer
#15
Michael Ziemke, Tejas Patil, Kyle Nolan, Darinee Tippimanchai, Stephen P Malkoski
OBJECTIVE: Smad4 is a tumor suppressor that transduces transforming growth factor beta signaling and regulates genomic stability. We previously found that Smad4 knockdown in vitro inhibited DNA repair and increased sensitivity to DNA topoisomerase inhibitors. In this study, we assessed the association between reduced Smad4 expression and DNA topoisomerase inhibitor sensitivity in human non-small cell lung cancer (NSCLC) patients and evaluated the relationship between genomic alterations of Smad4 and molecular alterations in DNA repair molecules...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28569042/exposure-response-analysis-of-necitumumab-efficacy-in-squamous-non-small-cell-lung-cancer-patients
#16
E Chigutsa, A J Long, J E Wallin
We sought to describe the exposure-response relationship of necitumumab efficacy in squamous non-small cell lung cancer patients and evaluate intrinsic and extrinsic patient descriptors that may guide dosing. SQUIRE was a phase III study comparing necitumumab in combination with gemcitabine and cisplatin vs. gemcitabine and cisplatin alone in 1,014 patients. An integrated model for tumor size dynamics and overall survival was developed, where reduction in tumor size results in a decrease in survival hazard...
August 2017: CPT: Pharmacometrics & Systems Pharmacology
https://www.readbyqxmd.com/read/28504964/meta-analysis-comparing-the-efficacy-of-nedaplatin-based-regimens-between-squamous-cell-and-non-squamous-cell-lung-cancers
#17
Yijun Tian, Qian Liu, Kongju Wu, Qian Chu, Yuan Chen, Kongming Wu
Non-small cell lung cancer (NSCLC) consists of several subtypes, including adenocarcinoma, squamous cell lung cancer, large cell lung cancer, and other rarer types. Platinum-based regimens are currently the standard for treatment of advanced NSCLC. Nedaplatin is reportedly associated with a high response rate in squamous cell lung cancer. However, the relevant studies are small and mainly descriptive. The purpose of this meta-analysis was therefore to compare the efficacy of nedaplatin in squamous cell lung cancer with that in non-squamous cell lung cancer...
April 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28500236/identification-of-the-serine-biosynthesis-pathway-as-a-critical-component-of-braf-inhibitor-resistance-of-melanoma-pancreatic-and-non-small-cell-lung-cancer-cells
#18
Kayleigh C Ross, Andrew J Andrews, Christopher D Marion, Timothy J Yen, Vikram Bhattacharjee
Metastatic melanoma cells commonly acquire resistance to BRAF V600E inhibitors (BRAFi). In this study, we identified serine biosynthesis as a critical mechanism of resistance. Proteomic assays revealed differential protein expression of serine biosynthetic enzymes PHGDH, PSPH, and PSAT1 following vemurafenib (BRAFi) treatment in sensitive versus acquired resistant melanoma cells. Ablation of PHGDH via siRNA sensitized acquired resistant cells to vemurafenib. Inhibiting the folate cycle, directly downstream of serine synthesis, with methotrexate also displayed similar sensitization...
August 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28489511/phase-iii-randomized-placebo-controlled-double-blind-trial-of-celecoxib-in-addition-to-standard-chemotherapy-for-advanced-non-small-cell-lung-cancer-with-cyclooxygenase-2-overexpression-calgb-30801-alliance
#19
RANDOMIZED CONTROLLED TRIAL
Martin J Edelman, Xiaofei Wang, Lydia Hodgson, Richard T Cheney, Maria Q Baggstrom, Sachdev P Thomas, Ajeet Gajra, Erin Bertino, Karen L Reckamp, Julian Molina, Joan H Schiller, Kisha Mitchell-Richards, Paula N Friedman, Jon Ritter, Ginger Milne, Olwen M Hahn, Thomas E Stinchcombe, Everett E Vokes
Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with worse outcome in non-small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B (CALGB) 30203, we found that the selective COX-2 inhibitor celecoxib in addition to chemotherapy in advanced NSCLC improved progression-free and overall survival in patients with moderate to high COX-2 expression by immunohistochemistry (IHC). CALGB 30801 (Alliance) was designed to prospectively confirm that finding. Patients and Methods Patients with NSCLC (stage IIIB with pleural effusion or stage IV according to American Joint Committee on Cancer [sixth edition] criteria) were preregistered, and biopsy specimens were analyzed for COX-2 by IHC...
July 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28472787/prognostic-index-for-survival-in-patients-with-advanced-non-small-cell-lung-cancer-treated-with-third-generation-agents
#20
Mari Kogo, Tomiko Sunaga, Shoko Nakamura, Takahiro Akita, Tatsuya Kurihara, Yusuke Shikama, Hiroaki Nakajima, Takashi Tobe, Keiichiro Yoneyama, Yuji Kiuchi
We retrospectively evaluated clinical data from patients with advanced non-small-cell lung cancer (NSCLC) treated with third-generation chemotherapy agents prior to treatment, to determine a reliable method for predicting prognosis in such patients. We analyzed 100 patients who received third-generation agents (paclitaxel, docetaxel, gemcitabine, irinotecan, and vinorelbine) for the treatment of advanced NSCLC. Factors significantly related to prognosis were evaluated using the Cox regression model, and the prognostic index (PI) was determined by combining these factors...
2017: Chemotherapy
keyword
keyword
43169
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"